Nordic Nanovector ASA: Invitation to First Quarter 2021 Results Presentation and Webcast
Nordic Nanovector ASA will report its first quarter 2021 results on May 26, 2021. A live presentation by the senior management team will be webcast at 8:30am CET on the same day. The webcast can be accessed from www.nordicnanovector.com. The results report and presentation will be available from 7:00am CEST on that day. Nordic Nanovector focuses on developing innovative therapies for haematological cancers, with its lead candidate, Betalutin®, designed to treat non-Hodgkin's lymphoma, a market projected to reach USD 26 billion by 2028.
- Nordic Nanovector is advancing its lead candidate, Betalutin®, for non-Hodgkin's lymphoma, targeting a substantial market.
- The company retains global marketing rights to Betalutin® and plans to commercialize it in major markets.
- None.
OSLO, Norway, May 20, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2021 on Wednesday, 26 May 2021.
A presentation by Nordic Nanovector's senior management team will be webcast live the same day at 8:30am CET.
The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.
The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2021 from 7:00am CEST the same day.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-invitation-to-first-quarter-2021-results-presentation-and-webcast-301295638.html
SOURCE Nordic Nanovector
